Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology

Journal of Allergy and Clinical Immunology

Volumn 115, Issue 6, 2005, Pages 1249-1253

  Fonacier, Luz ^a   Spergel, Jonathan ^b   Charlesworth, Ernest N ^c   Weldon, David ^d   Beltrani, Vincent ^e   Bernhisel Broadbent, Jan ^f   Boguniewicz, Mark ^g   Leung, Donald Y M ^g  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c Shannon Clinic   (United States)

^d SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^e Columbia University ^*  (United States)

^f INTERMOUNTAIN HEALTHCARE   (United States)

^g NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Atopic dermatitis; Pimecrolimus; Tacrolimus; Topical corticosteroids

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; PIMECROLIMUS; PSORALEN; STEROID; TACROLIMUS;

ARTICLE; ASEPTIC NECROSIS; ATOPIC DERMATITIS; B CELL LYMPHOMA; BONE DENSITY; BONE DISEASE; CANCER RISK; CARCINOGENICITY; CATARACT; CLINICAL TRIAL; CONSUMER; CUSHING SYNDROME; DATA ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG SAFETY; DRUG USE; DYSKERATOSIS; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HEADACHE; HEALTH CARE ORGANIZATION; HIP DISEASE; HUMAN; HYPERTENSION; INFECTION; LIVER TOXICITY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOPENIA; PATIENT CARE; PATIENT INFORMATION; PHOTOTHERAPY; POSTMARKETING SURVEILLANCE; PRECANCER; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; PUVA; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN CARE; SKIN DEFECT; SKIN IRRITATION; TELANGIECTASIA; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; CALCINEURIN; CHILD; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PRODUCT SURVEILLANCE, POSTMARKETING; TACROLIMUS;

EID: 20444506718     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2005.04.006     Document Type: Article

References (51)

1. D.Y.M. Leung, and T. Bieber Atopic dermatitis Lancet 361 2003 151 160
2. J.M. Spergel, and A.S. Paller Atopic dermatitis and the atopic march J Allergy Clin Immunol 112 suppl 2003 S118 S127
3. C. Miranda, A. Busacker, S. Balzar, J. Trudeau, and S.E. Wenzel Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation J Allergy Clin Immunol 113 2004 101 108
4. S. Illi, E. von Mutius, S. Lau, R. Nickel, C. Gruber, and B. Niggemann The natural course of atopic dermatitis from birth to age 7 years and the association with asthma J Allergy Clin Immunol 113 2004 925 931
5. Novartis and Fujisawa FDA Briefing Statements. Pediatric Advisory Committee Meeting of the US Food Drug Administration. Washington, DC, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm. Accessed March 16, 2005.
6. J. Harper, A. Green, G. Scott, E. Gruendl, B. Dorobek, and M. Cardno First experience of topical SDZ ASM 981 in children with atopic dermatitis Br J Dermatol 144 2001 781 787
7. Protopic (Tacrolimus) Ointment New Drug Application 50-777. Approval date 12/8/2000. Available at: http://www.fda.gov/cder/foi/nda/2000/50777_protopic. htm. Accessed March 16, 2005.
8. E.J. Van Leent, M.E. Ebelin, P. Burtin, B. Dorobek, P.I. Spuls, and J.D. Bos Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis Dermatology 204 2002 63 68
9. S. Reitamo, A. Wollenberg, E. Schopf, J.L. Perrot, R. Marks, and T. Ruzicka Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group Arch Dermatol 136 2000 999 1006
10. L.A.G. Ries M.P. Eisner C.L. Kosary B.F. Hankey B.A. Miller L. Clegg SEER cancer statistics review, 1975-2001 2004 National Cancer Institute Bethesda (MD) Available at: http://seer.cancer.gov/csr/1975_2001/ Accessed March 16, 2005
11. D.L. Miller, and M.A. Weinstock Nonmelanoma skin cancer in the United States: incidence J Am Acad Dermatol 30 1994 774 778
12. National Cancer Institute. Probability of developing non-Hodgkin's lymphoma. Available at: http://seer.cancer.gov/faststats/html/dev_nhl.html.
13. K.A. Papp, K. Breuer, M. Meurer, J.P. Ortonne, P.C. Potter, and Y. de Prost Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination J Am Acad Dermatol 52 2005 247 253
14. Stiehm E, Roberts R, Kaplan M, Corren J, Jaracz E, Rico M. Pneumococcal seroconversion after vaccination in children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol. In press 2005.
15. U. Wahn, J.D. Bos, M. Goodfield, R. Caputo, K. Papp, and A. Manjra Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children Pediatrics 110 2002 e2
16. K.A. Papp, T. Werfel, R. Folster-Holst, J.P. Ortonne, P.C. Potter, and Y. de Prost Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study J Am Acad Dermatol 52 2005 240 246
17. V.C. Ho, A. Gupta, R. Kaufmann, G. Todd, F. Vanaclocha, and R. Takaoka Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants J Pediatr 142 2003 155 162
18. S. Kang, A.W. Lucky, D. Pariser, I. Lawrence, and J.M. Hanifin Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children J Am Acad Dermatol 44 suppl 2001 S58 S64
19. A. Kapp, K. Papp, A. Bingham, R. Folster-Holst, J.P. Ortonne, and P.C. Potter Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug J Allergy Clin Immunol 110 2002 277 284
20. Y. Zhang, T.R. Holford, B. Leaderer, S.H. Zahm, P. Boyle, and L.M. Morton Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women Cancer Causes Control 15 2004 419 428
21. M.R. Karagas, G.L. Cushing Jr., E.R. Greenberg, L.A. Mott, S.K. Spencer, and D.W. Nierenberg Non-melanoma skin cancers and glucocorticoid therapy Br J Cancer 85 2001 683 686
22. H.T. Sorensen, L. Mellemkjaer, G.L. Nielsen, J.A. Baron, J.H. Olsen, and M.R. Karagas Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study J Natl Cancer Inst 96 2004 709 711
23. R.S. Stern, and N. Laird The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study Cancer 73 1994 2759 2764
24. B. Kirby, C.M. Owen, R.W. Blewitt, and V.M. Yates Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy J Am Acad Dermatol 47 suppl 2002 S165 S167
25. J.L. Lim, and R.S. Stern High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet a-treated patients J Invest Dermatol 124 2005 505 513
26. K. Momtaz, and T.B. Fitzpatrick The benefits and risks of long-term PUVA photochemotherapy Dermatol Clin 16 1998 227 234
27. I.M. Zonneveld, M.A. De Rie, R.C. Beljaards, H.J. Van Der Rhee, J. Wuite, and J. Zeegelaar The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens Br J Dermatol 135 suppl 48 1996 15 20
28. M.C. van Praag, L.N. Tseng, A.M. Mommaas, B.W. Boom, and B.J. Vermeer Minimising the risks of PUVA treatment Drug Saf 8 1993 340 349
29. A. Sinha, S. Velangi, and S. Natarajan Non-Hodgkin's lymphoma following treatment of atopic eczema with cyclosporin A Acta Derm Venereol 84 2004 327 328
30. T.Y. Chuang, L.A. Heinrich, M.D. Schultz, G.T. Reizner, R.C. Kumm, and D.J. Cripps PUVA and skin cancer. A historical cohort study on 492 patients J Am Acad Dermatol 26 1992 173 177
31. R.S. Stern The risk of melanoma in association with long-term exposure to PUVA J Am Acad Dermatol 44 2001 755 761
32. J. Dantal, M. Hourmant, D. Cantarovich, M. Giral, G. Blancho, and B. Dreno Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens Lancet 351 1998 623 628
33. M. Herman, T. Weinstein, A. Korzets, A. Chagnac, Y. Ori, and D. Zevin Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients J Lab Clin Med 137 2001 14 20
34. M. Lebwohl, and S. Ali Treatment of psoriasis. Part 1. Topical therapy and phototherapy J Am Acad Dermatol 45 2001 487 498 quiz 499-502
35. M.P. Sheehan, D.J. Atherton, P. Norris, and J. Hawk Oral psoralen photochemotherapy in severe childhood atopic eczema: an update Br J Dermatol 129 1993 431 436
36. R.S. Stern, K.T. Nichols, and L.H. Vakeva Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study N Engl J Med 336 1997 1041 1045
37. H.C. Korting, A. Unholzer, M. Schafer-Korting, I. Tausch, J. Gassmueller, and K.H. Nietsch Different skin thinning potential of equipotent medium-strength glucocorticoids Skin Pharmacol Appl Skin Physiol 15 2002 85 91
38. J. Serup, and P. Holm Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo Dermatologica 170 1985 189 194
39. J.A. Ellison, L. Patel, D.W. Ray, T.J. David, and P.E. Clayton Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis Pediatrics 105 2000 794 799
40. M. Turpeinen, O.P. Salo, and S. Leisti Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease Br J Dermatol 115 1986 475 484
41. A.W. Lucky, G.D. Grote, J.L. Williams, M.R. Tuley, J.M. Czernielewski, and T.M. Dolak Effect of desonide ointment, 0.05%, on the hypothalamic- pituitary-adrenal axis of children with atopic dermatitis Cutis 59 1997 151 153
42. K. Matsuda, T. Katsunuma, Y. Iikura, H. Kato, H. Saito, and A. Akasawa Adrenocortical function in patients with severe atopic dermatitis Ann Allergy Asthma Immunol 85 2000 35 39
43. Cook D. Nonprescription Drugs Advisory Committee and the Dermatologic and Opthalmic Drug Advisory Committee. March 24, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4099S1_03_FDA-Cook_files/ frame.htm#slide0173.htm. Accessed March 16, 2005.
44. K. Aalto-Korte, and M. Turpeinen Bone mineral density in patients with atopic dermatitis Br J Dermatol 136 1997 172 175
45. R.A. Covar, D.Y. Leung, D. McCormick, J. Steelman, P. Zeitler, and J.D. Spahn Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma J Allergy Clin Immunol 106 2000 651 659
46. A. Akhavan, and D. Rudikoff The treatment of atopic dermatitis with systemic immunosuppressive agents Clin Dermatol 21 2003 225 240
47. S. Reitamo, J. Rissanen, A. Remitz, H. Granlund, P. Erkko, and P. Elg Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial J Invest Dermatol 111 1998 396 398
48. J.D. Bos Topical tacrolimus and pimecrolimus are not associated with skin atrophy Br J Dermatol 146 2002 342 343
49. M. Boguniewicz, L.F. Eichenfield, and T. Hultsch Current management of atopic dermatitis and interruption of the atopic march J Allergy Clin Immunol 112 suppl 2003 S140 S150
50. S. Vitko, and O. Viklicky Cyclosporine renal dysfunction Transplant Proc 36 suppl 2004 243S 247S
51. R. Sidbury, and J.M. Hanifin Systemic therapy of atopic dermatitis Clin Exp Dermatol 25 2000 559 566